The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Neurodegenerative disease: models, mechanisms, and a new hope
Open accessAbstract
Neurodegeneration is a feature of many debilitating, incurable diseases that are rapidly rising in prevalence, such as Parkinson's disease. There is an urgent need to develop new and more effective therapeutic strategies to combat these devastating diseases. Models – from cell-based systems, to unicellular organisms, to complex animals – have proven to be a useful tool to help the research community shed light on the mechanisms underlying neurodegenerative diseases, and these advances have now begun to provide promising therapeutic avenues. In this themed issue of Disease Models & Mechanisms, a special collection of articles focused on neurodegenerative diseases is introduced. The collection includes original research articles that provide new insights into the complex pathophysiology of such diseases, revealing candidate biomarkers or therapeutic targets. Some of the articles describe a new disease model that enables deeper exploration of key mechanisms. We also present a series of reviews that highlight some of the recent translational advances made in studies of neurodegenerative diseases. In this Editorial, we summarize the articles featured in this collection, emphasizing the impact that model-based studies have made in this exciting area of research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Decoding ALS: from genes to mechanism
Taylor, J. P., Brown, R. H., & Cleveland, D. W. (2016) · Nature · doi:10.1038/nature20413 · Cited by 2,066
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture
Paşca, A. M., Sloan, S. A., Clarke, L. E., Tian, Y., Makinson, C. D., Huber, N., Kim, C. H., Park, J.-Y., O'Rourke, N. A., Nguyen, K. D., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3415 · Cited by 1,609
α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models
Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., et al. (2006) · Science · doi:10.1126/science.1129462 · Cited by 1,376
Self-citationAtaxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS
Elden, A. C., Kim, H.-J., Hart, M. P., Chen-Plotkin, A. S., Johnson, B. S., Fang, X., Armakola, M., Geser, F., Greene, R., Lu, M. M., et al. (2010) · Nature · doi:10.1038/nature09320 · Cited by 1,325
Self-citationAggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,228
Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease
Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M.-Y., & Bonini, N. M. (2002) · Science · doi:10.1126/science.1067389 · Cited by 1,227 · cited 1×
“…key insights into disease mechanisms (Link, 1995; Krobitsch and Lindquist, 2000; Boillee et al., 2006; Bruijn et al., 1998; Yamamoto et al., 2000; Auluck et al., 2002; Outeiro and Lindquist, 2003; Cooper et al., 2006; Gitler et al., 2008, 2009; Elden et al., 2010; Couthouis et al., 2011;…”
BackgroundAgeing, neurodegeneration and brain rejuvenation
Wyss-Coray, T. (2016) · Nature · doi:10.1038/nature20411 · Cited by 1,147
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“Further, these disorders can exhibit varying symptoms like cognitive decline, slow movement, tremors, memory loss, depression, speaking problems, muscle stiffness [460, 461].”
BackgroundPhase separation and neurodegenerative diseases: a disturbance in the force
Zbinden, A., Pérez-Berlanga, M., De Rossi, P., & Polymenidou, M. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.09.014 · Cited by 500
Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders
Enogieru, A. B., Haylett, W., Hiss, D. C., Bardien, S., & Ekpo, O. E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6241017 · Cited by 476
Redox Signaling by Reactive Electrophiles and Oxidants
Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 359
Biomedical Applications and Bioavailability of Curcumin—An Updated Overview
Sohn, S.-I., Priya, A., Balasubramaniam, B., Muthuramalingam, P., Sivasankar, C., Selvaraj, A., Valliammai, A., Jothi, R., & Pandian, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122102 · Cited by 305
Cellular functions of the protein kinase ATM and their relevance to human disease
Lee, J.-H., & Paull, T. T. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00394-2 · Cited by 289
Pohl, F., & Kong Thoo Lin, P. (2018) · Molecules · doi:10.3390/molecules23123283 · Cited by 272
Kumar, V., Kundu, S., Singh, A., & Singh, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666210609160017 · Cited by 210
Phlorotannins: A review on biosynthesis, chemistry and bioactivity
Shrestha, S., Zhang, W., & Smid, S. D. (2021) · Food Bioscience · doi:10.1016/j.fbio.2020.100832 · Cited by 155
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Sun, M., Ma, K., Wen, J., Wang, G., Zhang, C., Li, Q., Bao, X., & Wang, H. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190872 · Cited by 113
MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders
Han, D., Dong, X., Zheng, D., & Nao, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01555 · Cited by 90
Thakur, S., Doshi, J., Pati, S., Rathore, S., Sako, C., Bilello, M., Ha, S. M., Shukla, G., Flanders, A., Kotrotsou, A., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117081 · Cited by 84
Physical Exercise-Induced Myokines in Neurodegenerative Diseases
Lee, B., Shin, M., Park, Y., Won, S.-Y., & Cho, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115795 · Cited by 79
Fang, X., Zhou, X., Miao, Y., Han, Y., Wei, J., & Chen, T. (2020) · AMB Express · doi:10.1186/s13568-020-01014-6 · Cited by 70
Riganello, F., Larroque, S. K., Bahri, M. A., Heine, L., Martial, C., Carrière, M., Charland-Verville, V., Aubinet, C., Vanhaudenhuyse, A., Chatelle, C., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00769 · Cited by 70
Acoustofluidic assembly of 3D neurospheroids to model Alzheimer's disease
Cai, H., Ao, Z., Hu, L., Moon, Y., Wu, Z., Lu, H.-C., Kim, J., & Guo, F. (2020) · The Analyst · doi:10.1039/d0an01373k · Cited by 70
Repetitive elements in aging and neurodegeneration
Copley, K. E., & Shorter, J. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.02.008 · Cited by 70
Self-citationKaya, Z. B., Santiago-Padilla, V., Lim, M., Boschen, S. L., Atilla, P., & McLean, P. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-55516-5 · Cited by 58
Role of hydrogen sulfide in health and disease
Jin, Y., Yuan, H., Liu, Y., Zhu, Y., Wang, Y., Liang, X., Gao, W., Ren, Z., Ji, X., & Wu, D. (2024) · MedComm · doi:10.1002/mco2.661 · Cited by 54
Ainani, H., Bouchmaa, N., Ben Mrid, R., & El Fatimy, R. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106011 · Cited by 54
Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future
Hu, M.-L., Pan, Y.-R., Yong, Y.-Y., Liu, Y., Yu, L., Qin, D.-L., Qiao, G., Law, B. Y.-K., Wu, J.-M., Zhou, X.-G., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102078 · Cited by 44
Dziedzic, A., Miller, E., Saluk-Bijak, J., & Bijak, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051852 · Cited by 38
Cell death assays for neurodegenerative disease drug discovery
Linsley, J. W., Reisine, T., & Finkbeiner, S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1623784 · Cited by 32
Impact of Heat Shock Proteins in Neurodegeneration: Possible Therapeutical Targets
Beretta, G., & Shala, A. L. (2022) · Annals of Neurosciences · doi:10.1177/09727531211070528 · Cited by 32
Lobine, D., Sadeer, N., Jugreet, S., Suroowan, S., Keenoo, B. S., Imran, M., Venugopala, K. N., Ibrahim, F. M., Zengin, G., & Mahomoodally, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210412095251 · Cited by 32
Chitinase Signature in the Plasticity of Neurodegenerative Diseases
Russo, C., Valle, M. S., Casabona, A., & Malaguarnera, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076301 · Cited by 29
Sanfilippo, C., Castrogiovanni, P., Imbesi, R., & Di Rosa, M. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01667-9 · Cited by 26
Metadata
- Authors
- Gitler, A. D., Dhillon, P., & Shorter, J.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2017-05-01
- Volume
- 10
- Issue
- 5
- Pages
- 499-502
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2611631440
- Cited by
- 739
- References
- 46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.